[68Ga]Ga-DOTA-FAPI-04 PET/MR in patients with acute myocardial infarction: potential role of predicting left ventricular remodeling
Min Zhang, Weiwei Quan, Tianqi Zhu, Shuo Feng, Xin‐Yun Huang, Hongping Meng, Run Du, Zhengbin Zhu, Xuezheng Qu, Ping Li, Yuke Cui, Kuangyu Shi, Xiaoxiang Yan, Ruiyan Zhang, Biao Li
Abstract
Abstract Purpose To assess predictive value of 68 Ga-labeled fibroblast activation protein inhibitor-04 ([ 68 Ga]Ga-DOTA-FAPI-04) PET/MR for late left ventricular (LV) remodeling in patients with ST-segment elevated myocardial infarction (STEMI). Methods Twenty-six patients with STEMI were included in the study. [ 68 Ga]Ga-DOTA-FAPI-04 PET/MR was performed at baseline and at average 12 months after STEMI. LV remodeling was defined as >10% increase in LV end-systolic volume (LVESV) from baseline to 12 months. Results The LV remodeling group demonstrated higher [ 68 Ga]Ga-DOTA-FAPI-04 uptake volume (UV) at baseline than the non-LV remodeling group ( p < 0.001). [ 68 Ga]Ga-DOTA-FAPI-04 UV at baseline was a significant predictor (OR = 1.048, p = 0.011) for LV remodeling at 12 months after STEMI. Compared to clinical information, MR imaging and cardiac function parameters at baseline, [ 68 Ga]Ga-DOTA-FAPI-04 UV demonstrated better predictive ability (AUC = 0.938, p < 0.001) for late LV remodeling, with sensitivity of 100.0% and specificity of 81.3%. Conclusions [ 68 Ga]Ga-DOTA-FAPI-04 PET/MR is an effective tool to non-invasively quantify myocardial fibroblasts activation, and baseline [ 68 Ga]Ga-DOTA-FAPI-04 UV may have potential predictive value for late LV remodeling.